Avitriptan
≈ 2 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Avitriptan ( ; development code BMS-180048) is an antimigraine drug of the triptan family which was never marketed. It acts as a serotonin 5-HT 1B and 5-HT 1D receptor agonist. The drug reached phase 3 clinical trials prior to the discontinuation of its development.
Avitriptan ( ; development code BMS-180048) is an antimigraine drug of the triptan family which was never marketed. It acts as a serotonin 5-HT 1B and 5-HT 1D receptor agonist. The drug reached phase 3 clinical trials prior to the discontinuation of its development. ==Pharmacology== Avitriptan acts as a selective serotonin 5-HT 1B and 5-HT 1D receptor agonist. It is also notable in being a weak serotonin 5-HT 2A receptor agonist ( = 123 nM), albeit with about two orders of magnitude lower activational potency than at the serotonin 5-HT 1B and 5-HT 1D receptors. Besides its activities at serotonin receptors, avitriptan has been found to act as a weak aryl hydrocarbon receptor agonist. ==Chemistry== Avitriptan is a triptan and a modified analogue of tryptamines like the psychedelic drug dimethyltryptamine (DMT). However, avitriptan itself is not technically a tryptamine as it features a propylamine side chain instead of the ethylamine side chain present in tryptamines. Besides this difference, avitriptan is substituted at the 5 position of the indole ring system and the amine moiety has been cyclized and extended. The predicted log P of avitriptan is 1.8. ==See also== Triptan Donitriptan ==References==
Text derived from https://en.wikipedia.org/w/index.php?oldid=1338399399 under CC BY-SA 4.0; modifications have been made.